AELIS FARMA SAS (AELIS.PA) Fundamental Analysis & Valuation

EPA:AELIS • FR0014007ZB4

Current stock price

1.33 EUR
-0.08 (-5.67%)
Last:

This AELIS.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. AELIS.PA Profitability Analysis

1.1 Basic Checks

  • AELIS had negative earnings in the past year.
  • AELIS had a negative operating cash flow in the past year.
  • AELIS had negative earnings in 4 of the past 5 years.
  • In the past 5 years AELIS reported 4 times negative operating cash flow.
AELIS.PA Yearly Net Income VS EBIT VS OCF VS FCFAELIS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

1.2 Ratios

  • The Return On Assets of AELIS (-52.61%) is worse than 67.09% of its industry peers.
  • Looking at the Return On Equity, with a value of -134.05%, AELIS is in line with its industry, outperforming 45.57% of the companies in the same industry.
Industry RankSector Rank
ROA -52.61%
ROE -134.05%
ROIC N/A
ROA(3y)-31.08%
ROA(5y)-24.2%
ROE(3y)-61.94%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AELIS.PA Yearly ROA, ROE, ROICAELIS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for AELIS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AELIS.PA Yearly Profit, Operating, Gross MarginsAELIS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. AELIS.PA Health Analysis

2.1 Basic Checks

  • AELIS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • AELIS has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, AELIS has more shares outstanding
  • Compared to 1 year ago, AELIS has a worse debt to assets ratio.
AELIS.PA Yearly Shares OutstandingAELIS.PA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
AELIS.PA Yearly Total Debt VS Total AssetsAELIS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • A Debt/Equity ratio of 0.74 indicates that AELIS is somewhat dependend on debt financing.
  • AELIS has a Debt to Equity ratio (0.74) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC7.33%
AELIS.PA Yearly LT Debt VS Equity VS FCFAELIS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

  • A Current Ratio of 3.18 indicates that AELIS has no problem at all paying its short term obligations.
  • The Current ratio of AELIS (3.18) is better than 68.35% of its industry peers.
  • A Quick Ratio of 3.18 indicates that AELIS has no problem at all paying its short term obligations.
  • The Quick ratio of AELIS (3.18) is better than 70.89% of its industry peers.
Industry RankSector Rank
Current Ratio 3.18
Quick Ratio 3.18
AELIS.PA Yearly Current Assets VS Current LiabilitesAELIS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. AELIS.PA Growth Analysis

3.1 Past

  • AELIS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -13.00%.
  • Looking at the last year, AELIS shows a very negative growth in Revenue. The Revenue has decreased by -94.09% in the last year.
  • The Revenue for AELIS have been decreasing by -33.42% on average. This is quite bad
EPS 1Y (TTM)-13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.8%
Revenue 1Y (TTM)-94.09%
Revenue growth 3Y-33.42%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • AELIS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 146.58% yearly.
  • The Revenue is expected to grow by 88.24% on average over the next years. This is a very strong growth
EPS Next Y-131.58%
EPS Next 2Y70.14%
EPS Next 3Y146.58%
EPS Next 5YN/A
Revenue Next Year-52.86%
Revenue Next 2Y33.1%
Revenue Next 3Y88.24%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AELIS.PA Yearly Revenue VS EstimatesAELIS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M
AELIS.PA Yearly EPS VS EstimatesAELIS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 1 2

More info and screens

Find the best growth stocksShow best growing peers

3

4. AELIS.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AELIS. In the last year negative earnings were reported.
  • AELIS is valuated cheaply with a Price/Forward Earnings ratio of 7.60.
  • Based on the Price/Forward Earnings ratio, AELIS is valued cheaper than 98.73% of the companies in the same industry.
  • AELIS is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.79, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 7.6
AELIS.PA Price Earnings VS Forward Price EarningsAELIS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AELIS.PA Per share dataAELIS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

  • AELIS's earnings are expected to grow with 146.58% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y70.14%
EPS Next 3Y146.58%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AELIS.PA Dividend Analysis

5.1 Amount

  • AELIS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AELIS.PA Fundamentals: All Metrics, Ratios and Statistics

AELIS FARMA SAS

EPA:AELIS (3/25/2026, 7:00:00 PM)

1.33

-0.08 (-5.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners28.04%
Inst Owner ChangeN/A
Ins Owners17.74%
Ins Owner ChangeN/A
Market Cap18.23M
Revenue(TTM)446.00K
Net Income(TTM)-8.20M
Analysts84.44
Price Target11.22 (743.61%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.6
P/S 40.88
P/FCF N/A
P/OCF N/A
P/B 2.98
P/tB 3.08
EV/EBITDA N/A
EPS(TTM)-0.6
EYN/A
EPS(NY)0.18
Fwd EY13.17%
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0.03
BVpS0.45
TBVpS0.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -52.61%
ROE -134.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.08%
ROA(5y)-24.2%
ROE(3y)-61.94%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.44%
Cap/Sales 6.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.18
Quick Ratio 3.18
Altman-Z N/A
F-Score2
WACC7.33%
ROIC/WACCN/A
Cap/Depr(3y)106.33%
Cap/Depr(5y)205.47%
Cap/Sales(3y)3.89%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.8%
EPS Next Y-131.58%
EPS Next 2Y70.14%
EPS Next 3Y146.58%
EPS Next 5YN/A
Revenue 1Y (TTM)-94.09%
Revenue growth 3Y-33.42%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-52.86%
Revenue Next 2Y33.1%
Revenue Next 3Y88.24%
Revenue Next 5YN/A
EBIT growth 1Y-6.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-114.29%
EBIT Next 3Y152.58%
EBIT Next 5YN/A
FCF growth 1Y40.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.71%
OCF growth 3YN/A
OCF growth 5YN/A

AELIS FARMA SAS / AELIS.PA Fundamental Analysis FAQ

What is the fundamental rating for AELIS stock?

ChartMill assigns a fundamental rating of 2 / 10 to AELIS.PA.


Can you provide the valuation status for AELIS FARMA SAS?

ChartMill assigns a valuation rating of 3 / 10 to AELIS FARMA SAS (AELIS.PA). This can be considered as Overvalued.


What is the profitability of AELIS stock?

AELIS FARMA SAS (AELIS.PA) has a profitability rating of 0 / 10.


What is the expected EPS growth for AELIS FARMA SAS (AELIS.PA) stock?

The Earnings per Share (EPS) of AELIS FARMA SAS (AELIS.PA) is expected to decline by -131.58% in the next year.